Tirzepatide

A dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist — the first in its class. FDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Clinical trials (SURMOUNT program) demonstrated average weight loss of 20–22.5% over 72 weeks — exceeding all prior anti-obesity peptides including semaglutide. Represents the second-generation GLP-1-based peptide drug class.